ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO918

Phenotype of SARS-CoV-2 Specific T and B Cells in Lymph Nodes of Patients With ESRD

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Frölke, Sophie Carmen, Amsterdam UMC Locatie AMC, Amsterdam, North Holland, Netherlands
  • Sri Pathmarajah, Danisha, Amsterdam UMC Locatie AMC, Amsterdam, North Holland, Netherlands
  • Remmerswaal, Ester B.M., Amsterdam UMC Locatie AMC, Amsterdam, North Holland, Netherlands
  • Bemelman, Frederike J., Amsterdam UMC Locatie AMC, Amsterdam, North Holland, Netherlands
Background

In patients with end-stage renal disease (ESRD), mean antibody concentrations following SARS-CoV-2 vaccination are lower than in the general population, which correlates with the risk of COVID-19 disease. For a high-affinity antibody response, germinal centre responses in lymph nodes (LN) are critical. However, current knowledge on SARS-CoV-2 specific B and T cell responses is almost exclusively based on peripheral blood (PB) mononuclear cells (MNC). Previous studies have shown that LN MNC differ substantially from their PB counterparts. We aim to study the functional and phenotypical differences between PB- and LN-derived SARS-CoV-2 specific B and T cells after vaccination in ESRD patients and compare these with their counterparts after infection.

Methods

MNC were isolated from PB and paired non-draining LN of ESRD patients, retrieved during kidney transplantation. Ten patients who received SARS-CoV-2 vaccination and five who suffered COVID-19 disease were included. SARS-CoV-2 spike specific T cells were phenotyped using HLA class I dextramers and for SARS-CoV-2 spike specific B cells spike-tetramers were used. Also, antibody levels and functions like neutralization of infectivity, phagocytosis, antibody-dependent cellular cytotoxicity and complement-mediated lysis of pathogens of infected cells were measured.

Results

An example of the SARS-CoV-2 specific T and B cell phenotyping in PB MNC of healthy controls is shown. Whether these cells are detectable in the non-draining LN of ESRD patients after SARS-CoV-2 vaccination or infection and if they functionally and phenotypically correlate with paired PB MNC is yet to be determined.

Conclusion

We aim to gain an invaluable insight into the underlying T- and B-cell-centred immunological processes in LN of ESRD patients in order to understand and optimize vaccine response.

SARS-CoV-2 specific T and B cell phenotyping in PB MNC of healthy controls